Last updated on September 2018

A Phase 3, Multicenter, Open-Label Extension Study Of Oral Ozanimod For Moderately To Severely Active Crohn's Disease

Brief description of study

This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

Clinical Study Identifier: TX212265

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.